Browse by author
Lookup NU author(s): Marsela Qesari,
Dr Lindsay Nicholson,
Professor Anne Dickinson,
Dr Xiao WangORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Allogeneic hematopoietic stem cell transplantation is associated with serious complications, and improvement of the overall clinical outcome of patients with hematological malignancies is necessary. During the last decades, posttransplant donor-derived adoptive cellular immunotherapeutic strategies have been progressively developed for the treatment of graft-versus-host disease (GvHD), infectious complications, and tumor relapses. To date, the common challenge of all these cell-based approaches is their implementation for clinical application. Establishing an appropriate manufacturing process, to guarantee safe and effective therapeutics with simultaneous consideration of economic requirements is one of the most critical hurdles. In this review, we will discuss the recent scientific findings, clinical experiences, and technological advances for cell processing toward the application of mesenchymal stromal cells as a therapy for treatment of severe GvHD, virus-specific T cells for targeting life-threating infections, and of chimeric antigen receptors-engineered T cells to treat relapsed leukemia.
Author(s): Reis M, Ogonek J, Qesari M, Borges NM, Nicholson L, Preussner L, Dickinson AM, Wang XN, Weissinger EM, Richter A
Publication type: Review
Publication status: Published
Journal: Frontiers in Immunology
Online publication date: 14/11/2016
Acceptance date: 26/10/2016
ISSN (print): 1664-3224
Publisher: FRONTIERS MEDIA SA